Incyte shares should be bought on any weakness, says JMP Securities

theflyonthewall.com

After the New England Journal of Medicine printed a letter reporting that a patient who had been taking Incyte's Jakafi developed a case of bilateral primary toxoplasmosis retinitis, JMP Securities is not worried by the news. The firm reports that no definite link between Jakafi and the condition was found, and that drugs often have adverse effects on a single patient. The firm reiterates a $29 price target and Outperform rating on the stock.

View Comments (0)